Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was issued on June 26, 2012. The document provides historical quarterly restatements for the full year 2011, aligning with reclassifications of turnover and core earnings published on March 28, 2012. The data is presented to assist comparability with future quarterly reporting of core operating profit by segment.
Key Financial Metrics (Full Year 2011)
| Metric | Value (£m) |
|---|---|
| Total Turnover | 27,387 |
| Pharmaceuticals and Vaccines Turnover | 22,112 |
| Consumer Healthcare Turnover | 5,275 |
| Core Operating Profit | 8,803 |
| Total Operating Profit | 7,807 |
| Non-core Items | (996) |
| Corporate and Other Unallocated Costs | (620) |
The filing does not provide specific data on cash flow, debt levels, or liquidity ratios.
Material Changes and Segment Performance
The filing details quarterly performance for 2011, highlighting the following trends:
- Turnover Growth: Total turnover increased from £6,585m in Q1 2011 to a peak of £7,104m in Q3 2011, settling at £6,978m in Q4 2011.
- Profitability: Core operating profit ranged from £2,044m in Q1 to £2,328m in Q3. Total operating profit was significantly impacted by non-core items, particularly in Q2 (£389m) and Q4 (£385m).
- Segment Contributions: The USA segment generated the highest turnover (£7,022m) and core operating profit (£4,646m) for the year. Europe followed with £5,700m turnover and £3,154m core profit.
- Reclassifications: A specific adjustment of £9 million of Relenza sales was reclassified from the EMAP segment to the "Other trading and unallocated pharmaceuticals and vaccines" segment for Q2 2011.
Guidance, Outlook, and Risks
GSK intends to report core operating profit by segment in future quarters. The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. Specific risk factors are referenced in the "Financial review & risk" section of the 2011 Annual Report (Exhibit 15.2). No specific financial guidance or outlook for 2012 is provided in this document.
Investor Verification Checklist
- Verify the impact of the £9 million Relenza sales reclassification on EMAP segment comparability.
- Review the 2011 Annual Report (Exhibit 15.2) for detailed risk factors affecting operations.
- Confirm the methodology for "Core Operating Profit" versus "Total Operating Profit" to understand the magnitude of non-core items (£996m for the full year).
- Check subsequent filings for the adoption of the new segment reporting format for 2012 quarters.